Press Releases for CBST

Press Releases
Analyst Choice Updated Analysis on DENTSPLY International Inc., PAETEC Holding Corp., Antigenics Inc., Cubist Pharmaceuticals Inc., Alkermes Inc. and Biogen Idec Inc.
Dyax Corp. Announces Third Quarter 2009 Financial Results
Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%
Dyax Corp. Announces Expanded Roles for Two Senior Management Executives As Company Advances Commercialization Plan
Cubist Pharmaceuticals to Present at Canaccord Adams 29th Annual Global Growth Conference
StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
Dyax Corp. Announces Second Quarter 2009 Financial Results
Third Rock Ventures Expands Team With Biotech Veterans
INSERTING and REPLACING Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Cubist Pharmaceuticals 2nd Quarter Total Net Revenues Up 28%
Evotec Announces Research Agreement On Fragment Based Screening Drug Discovery With Cubist Pharmaceuticals
Cubist Pharmaceuticals Announces Second Quarter 2009 Earnings Call
Cubist Pharmaceuticals Initiates Phase 2 Trial in Europe for Therapy to Reduce Blood Loss During Surgery in High Risk Patients
Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
INSERTING and REPLACING Cubist Pharmaceuticals to Present at June 2009 Investor Conferences
Cubist Pharmaceuticals to Present at June 2009 Investor Conferences
Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe’s Annual Globe 100 List of Best Performing Companies
Cubist Pharmaceuticals to Present at May 2009 Investor Conferences
Dyax Corp. Announces First Quarter 2009 Financial Results
Cubist Pharmaceuticals 1Q09 Total Net Revenues Up 37%; Total Net Revenues $121.1 Million; Net Product Revenues $114.6 Million
Cubist Pharmaceuticals to Announce Q109 Financial Results on Tuesday, April 21st, 2009
Beacon Equity Issues Trade Alerts on Market Movers: CBST, WDC, NVS, FDX, IBM, DNDN
WallStSense.Com Issues Free Ratings Report on GLBL, CPST, PRGO and CBST
Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
Cubist Pharmaceuticals to Present at Citi’s 4th Annual Citi Biotech Day
Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.
Dyax Amends Loan Agreement With Cowen Healthcare Royalty Partners for an Additional $15 Million
Cubist Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections
Cubist Pharmaceuticals Announces Start of First-in-Human Clinical Trial for Investigational New Drug for Clostridium difficile infections
Cubist Plans to Commence Patent Infringement Litigation against Teva Parenteral Medicines, Inc. In Response To ANDA filing
BenchmarkJournal.Com (Complimentary) Analyst Review for CBST, PENN, WERN and SHPGY
Cubist Pharmaceuticals Reports GAAP Diluted Net Income of $1.82 Per Share in Fourth Quarter 2008 and GAAP Diluted Net Income of $2.56 Per Share for Full Year 2008
Zacks PEG Ratio Strategy Highlights: Cubist Pharmaceuticals, Kendle International, Tower Group and VanceInfo Technologies.
Cubist Pharmaceuticals Announces Full Year 2008 Total Net Revenues of $433.6 Million
Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection
Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile - Jan 5 2009 12:42PM
Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile - Jan 5 2009 7:26AM
Cubist Pharmaceuticals to Present at RBC Capital Markets 2008 Healthcare Conference
Cubist Pharmaceuticals Names Santosh J. Vetticaden as Senior Vice President, Clinical Development and Chief Medical Officer
The Boston Globe names Cubist to Globe 100's Top Places to Work '08
Cubist Pharmaceuticals to Present at Oppenheimer's 19th Annual Healthcare Conference
Zacks Industry Rank Analysis Highlights: Abbot Laboratories, AstraZeneca, Chattem, Cubist Pharmaceuticals and ViroPharma
CUBICIN(R) Outcomes Registry and Experience (CORE(R)) Marks Milestone
Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN(R) Net Product Revenues $110.6 Million
Cubist Pharmaceuticals to Announce Third Quarter 2008 Financial Results on Thursday, October 16, 2008
Cubist Pharmaceuticals Opens New Research Facility at Lexington Headquarters
Cubist Pharmaceuticals Provides Update on Advancing Product Pipeline
Webcast Alert: Cubist Pharmaceutical's Investor Event
Cubist Pharmaceuticals to Host Investor Event: Act 2 - Raising the Curtain on Cubist's Pipeline
Cubist Pharmaceuticals to Present at September Investor Conferences
SilkRoad Technology Announces Q2 Results for 2008 - Aug 14 2008 11:54PM
Cubist Pharmaceuticals Reports First $100 Million Revenue Quarter; Q2 2008 Total Revenues $101.8 Million; Total Net Product Revenues $101.4 Million
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Cubist Pharmaceuticals to Announce Second Quarter 2008 Financial Results on Thursday, July 17, 2008
Cubist Pharmaceuticals Appoints Mark H.N. Corrigan, M.D., to Its Board of Directors
Cubist Pharmaceuticals Testifies on Need to Encourage Antibiotic Research and Development
Cubist Pharmaceuticals Appoints Nancy J. Hutson, Ph.D., to Its Board of Directors
Cubist Pharmaceuticals will Present at the Jefferies & Co. 2nd Annual Healthcare Conference on June 25th, 2008
Cubist Pharmaceuticals Announces the Adoption of Notice and Access Rule for Its 2008 Annual Meeting of Stockholders - Jun 1 2008 3:57PM
Cubist Pharmaceuticals to Present at May 2008 Investor Conferences
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
Cubist Pharmaceuticals Q1 2008 Revenues up 48%; Net Income up 220%: Total Revenues $88.3 Million; Net Product Revenues $87.9 Million
Cubist Pharmaceuticals to Announce First Quarter 2008 Financial Results on Thursday, April 17, 2008